CARFILNAT contains carfilzomib, a second-generation selective proteasome inhibitor. It blocks intracellular protein degradation pathways, leading to accumulation of defective proteins and apoptosis of cancer cells.
The drug shows high activity against multiple myeloma cells, including resistant forms.
Recommended for:
Carfilzomib is a modern agent with strong clinical evidence.
Studies demonstrate:
It is widely used in international treatment protocols for multiple myeloma.
The drug is indicated for the treatment of hematologic malignancies.
Main indications:
The mechanism involves proteasome inhibition, leading to accumulation of toxic proteins and cancer cell death.
The drug is administered intravenously as an infusion under medical supervision. The dosage, schedule, and duration of therapy are determined individually based on the patient's condition and treatment protocol. The solution is prepared immediately before administration in a clinical setting. Self-administration is not allowed.
